# POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

> **NCT03171389** · PHASE2 · UNKNOWN · sponsor: **Sebastian Bauer** · enrollment: 81 (estimated)

## Conditions studied

- GIST, Malignant
- KIT Exon 13 Mutation
- KIT Gene Mutation

## Interventions

- **DRUG:** Ponatinib 30 MG

## Key facts

- **NCT ID:** NCT03171389
- **Lead sponsor:** Sebastian Bauer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-22
- **Primary completion:** 2018-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2017-05-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03171389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03171389, "POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03171389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*